Theravance Biopharma Inc (TBPH) was Reiterated by Leerink Partners to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 29 from a previous price target of $26 . Leerink Partners advised their investors in a research report released on Jun 20, 2016.
Many Wall Street Analysts have commented on Theravance Biopharma Inc. Guggenheim Initiated Theravance Biopharma Inc on Jun 20, 2016 to “Buy”, Price Target of the shares are set at $30.Leerink Partners Initiated Theravance Biopharma Inc on May 12, 2016 to “Outperform”, Price Target of the shares are set at $26.Theravance Biopharma Inc was Downgraded by BofA/Merrill to ” Neutral” on May 5, 2016.
Theravance Biopharma Inc closed down -0.69 points or -3.07% at $21.82 with 5,00,637 shares getting traded on Friday. Post opening the session at $22.59, the shares hit an intraday low of $21.51 and an intraday high of $22.66 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 18, 2015, Junning Lee (Sr. VP, Technical Operations) purchased 9,000 shares at $12.90 per share price. According to the SEC, on Aug 18, 2015, Burton G Malkiel (director) purchased 10,000 shares at $12.92 per share price. On Aug 17, 2015, Renee D Gala (CFO) purchased 10,000 shares at $12.18 per share price, according to the Form-4 filing with the securities and exchange commission.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.